News
Scribe Files $107M IPO as Lilly’s $2.8B Psychedelic Bet Lifts the Sector
Gene-editing biotech Scribe Therapeutics filed for a ~$107 million IPO to fund its cholesterol-lowering gene-silencing therapy. Meanwhile, Eli Lilly’s $2.8 billion acquisition of psychedelic drugmaker AtaiBeckley has analysts calling it a “rising tide” for the entire space.
